ArticleDiabetes, obesity & metabolism2026
Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsTo quantify the incremental economic and utilization burden of comorbid obstructive sleep apnea (OSA) within an overweight to severely obese adult population. MATERIAL AND
methodsThis retrospective cohort study utilized 2016-2025 IQVIA PharMetrics Plus Closed Health Plan commercial claims data to identify overweight to severely obese adults aged 18-64 years. Patients with diagnosed OSA were propensity-score matched 1:1 to non-OSA controls. Generalized linear models were constructed to quantify the incremental burden of OSA through adjusted cost/rate ratios and average marginal effects (AMEs) over a 365-day follow up period. Outcomes were also stratified by obesity severity, cardiovascular disease (CVD), diabetes, sex, and baseline glucagon-like peptide-1 receptor agonist (GLP-1 RA) use.
resultsAmong OSA patients, 13 971 (99.9%) were successfully matched (total n = 27 942). Patients with OSA incurred significantly higher total healthcare costs compared to controls (adjusted cost ratio = 1.24; 95% CI = [1.20, 1.28]), corresponding to an AME of $6942 per patient. Costs were driven by routine disease management such as outpatient visits (AME = $2955) and prescription costs (AME = $3198). Subgroup analyses revealed that incremental costs were high among patients with CVD (AME = $9257) and notably, the incremental cost of OSA remained substantial even among chronic users of GLP-1 RAs (AME = $12359).
conclusionComorbid OSA is associated with a significant increase in total healthcare costs driven largely by outpatient and prescription costs. This burden was concentrated among patients with cardiovascular comorbidity and persisted among chronic GLP-1 RA users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.